Omnia Education

The Next Generation of Oral Contraception: Advances in Estrogens

The Next Generation of Oral Contraception: Advances in Estrogens
RestartResume

This article traces the evolution of estrogen in contraception, with a special focus on the concept of native estrogen with specific actions in tissues (NEST).

Available credits: 0.25

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    This article traces the evolution of estrogen in contraception, with a special focus on the concept of native estrogen with specific actions in tissues, or NEST. Research surrounding estetrols (E4), receptor binding, and target interactions demonstrate that E4 has high selectivity for the estrogen receptors. Clinical trial data are presented that support the view that E4 – a high NEST activity estrogen – is a safe and effective estrogen for use in combined oral contraceptives.

    This premise was borne out with the approval of an estetrol/drosperinone combined oral contraceptive by the US Food and Drug Administration in April 2021.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty
    Patricia Geraghty, MSN, FNP-BC, WHNP
    Director of Women’s Health
    Comprehensive Wellness
    Walnut Creek, CA

    Consulting Fees: AbbVie, Mayne Pharma

    Hugh S. Taylor, MD
    Chair, Dept of Obstetrics, Gynecology, and Reproductive Sciences
    Yale School of Medicine
    New Haven, CT 

    Patent Holder: DotLab

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Barry A. Fiedel, PhD, has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Lynne Kolton Schneider, PhD has nothing to disclose.
    • Robert Schneider, MSW has nothing to disclose.
    • Hugh S. Taylor, MD is a patent holder of DotLab.
  • Learning Objectives

    After completing this CME activity, participants will be better able to:

    • Understand the role of estrogens through a woman’s reproductive life cycle
    • Compare and contrast the regulatory roles of E1, E2, E3 and E4
    • Explain the pharmacology supporting the use of estetrol (E4) in combination oral contraceptives
  • Target Audience

    This activity is designed to meet the educational needs of obstetricians/gynecologists, nurse practitioners, physician assistants, nurses, certified nurse midwives, and primary care physicians with a focus on women’s health.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Commercial Support

    This activity is supported by an independent educational grant from Mayne Pharma. 

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

Register

We’re glad to see you’re enjoying Omnia Education…
but how about a more personalized experience?

Register for free